Ph.D., Vice President, Personalized Medicine; Scientific Director, Genospace, SCRI
Biography
Dr. McKenzie joined Sarah Cannon Research Institute (SCRI) in 2015 and serves as the vice president of SCRI’s Personalized Medicine Program. He also serves as the scientific director for Genospace, SCRI’s precision medicine software platform. McKenzie has more than 10 years of basic science and translational research experience in oncology. In his role, Dr. McKenzie is responsible for providing scientific and operational oversight for implementing the personalized medicine strategy at SCRI. He and the personalized medicine program provide scientific, consultative and programmatic services to clinical research investigators, study sponsors, research personnel and other healthcare providers to advance molecular profiling efforts at SCRI. As scientific director at Genospace, McKenzie is responsible for providing scientific and strategic guidance to data science and product development activities. Prior to joining SCRI, Dr. McKenzie was a research fellow at Vanderbilt University’s Vanderbilt-Ingram Cancer Center. He earned a Doctor of Philosophy in pharmacology from The University of Vermont.
Session Abstract – PMWC 2023 Silicon Valley
Track 4 - January 26 9.00 A.M.-4.30 P.M.
Track Chair: Cindy Perettie, Roche
- PMWC 2023 Award Ceremony
- Luis Alberto Diaz Jr., MSK
- Razelle Kurzrock, Medical College of Wisconsin - Non-invasive Liquid Biopsy Techniques (PANEL)
Chair: Razelle Kurzrock, Medical College of Wisconsin
- Apostolia Tsimberidou, MD Anderson
- Mandana Kamgar, MD Medical College of Wisconsin
- Mina Nikanjam, UCSD
- Ash Alizadeh, Stanford University - Liquid Biopsy Challenges and Limitations (PANEL)
Chair: Victor Lin, Mary Bird Perkins
- Luis Alberto Diaz Jr., MSK
- Maximilian Diehn, Stanford
- Dana Dilbeck, Agilent
- Emma Shtivelman, Cancer Commons - Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
Chair: Cindy Perettie, Roche Diagnostics
- Eric Peters, Genenetch
- Andrew Mckenzie, Sarah Cannon
- Yang Pan, Gilead
- Alan Sandler, Mirati Therapeutics - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
Chair: Tom Beer, Exact Sceinces
- Liquid Biopsy for Early Cancer Detection (PANEL)
Chair: Priti Hegde, Foundation Medicine
- Daniel Kim, UCSC
- Mike Nolan, Freenome
- Jeffrey Venstrom, Grail Bio
- Kathryn Phillips, UCSF
- Lon Castle, eviCore healthcare
- Tom Beer, Exact Sciences - Liquid Biopsy for Minimal Residual Disease (PANEL)
Chair: Minetta Liu, Natera
- Peter Bach, Delfi diagnostics
- Laura Vantveer, UCSF
- Susan Bobulsky, Adaptive
- Joshua Cohen, Johns Hopkins
- PMWC Showcase
- Harmeet Dhani, Biological Dynamics
- Varsha Rao, Claret Bio - PMWC NCI Showcase
- Xianghong Jasmine Zhou, EarlyDiagnostics
